News | September 11, 2009

UVA to Open World's First Fully-Dedicated Focused Ultrasound Surgery Center

September 11, 2009 - The University of Virginia Health System plans to open a new MR Guided Focused Ultrasound (MRgFUS) Surgery Center, which will be the first facility in the world used exclusively for performing research and providing treatments with MRgFUS.

Located on the grounds of the UVA Health System, the new center will launch a robust, multidisciplinary research program to investigate the safety and efficacy of MRgFUS in treating brain, breast, prostate, bone and liver tumors and conditions such as epilepsy, stroke, chronic pain, Parkinson's disease and essential tremor.

Beginning in October, the center will also offer FDA-approved MRgFUS treatments to women with small, benign tumors known as uterine fibroids. Clinical offerings will expand as focused ultrasound treatments for other conditions are developed and receive FDA-approval.

"The opening of this facility is an exciting development," said James M. Larner, M.D., chairman of UVA's Department of Radiation Oncology and director of the new center. "Our facility is the first to have a fully-dedicated magnet, meaning it will be used exclusively for MRgFUS research and treatments. Full-time access to equipment should accelerate the pace of our research and place UVA at the forefront of this emerging area of healthcare."

UVA specialists in anesthesiology, biomedical engineering, gynecology, neurology, neurosurgery, oncology, radiology, radiation oncology surgery and urology will conduct research at the center.

Alan H. Matsumoto, M.D., interim chairman, Department of Radiology and co-director of the new center, will provide focused ultrasound treatments to patients with uterine fibroids. "This therapy will add an important option to the spectrum of treatments we offer for uterine fibroids. For some women, this noninvasive procedure will be the ideal choice," he said.

MRgFUS procedures are performed on an outpatient basis without general anesthesia and cause minimal discomfort and few complications, allowing patients to recover rapidly.

Hailed as a breakthrough technology, MRgFUS integrates the visualization capabilities of magnetic resonance imaging with the intense energy that is created when multiple waves of high frequency ultrasound are directed to a treatment site. Highly precise, MRgFUS can target treatment sites as small as one millimeter in diameter.

Single waves of focused ultrasound are as harmless to body tissue as those emitted during diagnostic ultrasound testing. However, when waves intersect - which is what happens during focused ultrasound treatments - they become powerful enough to destroy tumors and liquefy blood clots.

Targeted drug delivery is another promising use of focused ultrasound. In such procedures, patients receive injections of chemotherapy or other drugs, which remain inactive while the bloodstream carries them to the treatment site. When the drugs reach the targeted tumor or tissue, clinicians activate them using waves of MRgFUS energy. Such precise and localized drug delivery is expected to eliminate the side effects of chemotherapy and other powerful pharmaceuticals.

Currently, MRgFUS has one FDA-approved application - the treatment of uterine fibroids - and more uses are anticipated. Clinical trials in several countries are now evaluating focused ultrasound's effectiveness in treating metastatic bone tumors, breast and brain cancer, and other malignancies.

Neal F. Kassell, M.D., professor of neurosurgery at UVA, has been a key force behind the opening of the new MRgFUS Surgery Center. "Focused ultrasound may be the most important therapeutic advancement since the scalpel and could affect millions of people around the globe," he says. To accelerate MRgFUS research and development, Kassell helped establish the non-profit Focused Ultrasound Surgery Foundation in 2006. He now serves as the organization's chairman.

Earlier this year, the FUS Surgery Foundation donated $3.1 million to UVA's new facility, designating it as the first of three centers of excellence it will fund during the next two years. The Foundation is co-sponsoring the September 14 symposium and dedication ceremony at UVA.

Additional support for the new facility includes a $4.0 million grant from the Commonwealth of Virginia and in-kind giving from focused ultrasound equipment manufacturer, InSightec, and MRI scanner producer, General Electric.

For more information: www.healthsystem.virginia.edu

Related Content

Bay Labs Announces New Data on EchoGPS, AutoEF AI Software at ACC.19
News | Cardiovascular Ultrasound | March 15, 2019
Artificial intelligence (AI) company Bay Labs announced the presentation of two studies assessing performance of the...
Esaote Introduces MyLab X8 Ultrasound Platform
News | Ultrasound Imaging | March 13, 2019
Esaote announced the launch of MyLab X8, a high-performance, versatile ultrasound platform to support hospitals and...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Canon Medical Systems introduces 33 MHz Ultra-High Frequency Ultrasound Transducer
News | Ultrasound Imaging | March 01, 2019
March 1, 2019 — Expanding its advanced, high-performing Aplio i-series...
ACR Helping Radiologists Avoid Massive Ultrasound Reimbursement Cuts
News | Ultrasound Imaging | February 27, 2019
The American College of Radiology (ACR) urges radiologists and allied professionals to help the college ward off $112...
Fujifilm Exhibits Enterprise Imaging Solutions and Artificial Intelligence Initiative at HIMSS 2019
News | Enterprise Imaging | February 15, 2019
Fujifilm Medical Systems U.S.A. Inc. and Fujifilm SonoSite Inc. showcased their enterprise imaging and informatics...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
An example of Philips' TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips' TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. 

Feature | Ultrasound Imaging | February 07, 2019 | Dave Fornell, Editor
Here is a list of six key trends in ul...
Epiq Elite for Obstetrics and Gynecology delivers high image quality and lifelike 3-D scans

The Epiq Elite for Obstetrics & Gynecology. Image courtesy of Philips Healthcare.

Technology | Ultrasound Imaging | February 07, 2019
Philips announced the launch of the Epiq Elite ultrasound system, a new premium ultrasound that combines the latest...
ASE Releases Guidelines for Transesophageal Echo in Congenital Heart Disease
News | Ultrasound Transesophageal echo (TEE) | February 05, 2019
February 5, 2019 – The American Society of Echocardiography (ASE) released a new document that provides a comprehensi